BioSpace News Archive

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $2.15 per share on its outstanding shares of Common Stock.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that it has resubmitted its New Drug Application (NDA) for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis, to the U.S. Food and Drug Administration (FDA).

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) today announced that CEO Harlan Weisman, M.D. will be presenting a corporate overview at the 2023 Jefferies Healthcare Conference being held in-person in New York, NY on June 7-9, 2023.

Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced that it has commenced an underwritten public offering of its common stock.

Atea Pharmaceuticals, Inc. confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Atea’s programs.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

GENFIT announced the publication of the development and validation of NIS2+™ in the Journal of Hepatology.

CooperCompanies, will participate in the Jefferies Healthcare Conference on Thursday, June 8, 2023.

Veeva Systems (NYSE: VEEV) and UCB , a global biopharmaceutical company, today announced a collaboration that will focus on technology-driven solutions aimed at improving the patient experience and trial efficiency.